Learn about Mycobacterium Avium Complex (MAC) infection diagnosis, including clinical documentation requirements, ICD-10 codes (A31.0, R78.89), SNOMED CT concepts, and laboratory testing for MAC. Find information on MAC treatment, symptoms, and prevention strategies for healthcare professionals. Understand the importance of accurate MAC diagnosis coding and documentation for optimal patient care and reimbursement. Explore resources for clinicians on managing and documenting MAC infections effectively.
Also known as
Pulmonary mycobacterial disease
Lung infection caused by Mycobacterium avium complex (MAC).
Other mycobacterial diseases
MAC infections affecting sites other than the lungs.
Other specified bacterial infections
MAC infection as a secondary diagnosis or in unspecified locations.
Other specified abnormal findings
Used for incidental findings of MAC without clinical significance.
Follow this step-by-step guide to choose the correct ICD-10 code.
Is the MAC infection pulmonary?
Yes
Is it disseminated?
No
Is it disseminated?
When to use each related code
| Description |
|---|
| Mycobacterium Avium Complex Infection |
| Tuberculosis |
| Histoplasmosis |
Inaccurate coding due to similar mycobacterial infections. Specificity between pulmonary and disseminated MAC is crucial for correct ICD-10-CM code assignment (A31.0 vs. A31.8).
Insufficient documentation of treatment response and drug susceptibility testing impacts coding accuracy and medical necessity audits for prolonged therapy.
Overlooking underlying conditions like HIV or COPD that influence MAC severity and treatment. Accurate comorbidity coding is essential for risk adjustment and reimbursement.
Patient presents with signs and symptoms suggestive of Mycobacterium Avium Complex (MAC) infection, including persistent cough, fever, night sweats, weight loss, and fatigue. Differential diagnosis includes tuberculosis, fungal infections, and other pulmonary diseases. Sputum culture, bronchoalveolar lavage, or lymph node biopsy was performed for acid-fast bacilli (AFB) smear and culture, with results indicative of MAC. Polymerase chain reaction (PCR) testing may have been utilized for species identification (Mycobacterium avium, Mycobacterium intracellulare). Chest X-ray or CT scan may reveal nodular or cavitary lesions. The patient's medical history, including immunosuppression (HIV infection, organ transplantation), underlying lung disease (COPD, bronchiectasis), and previous nontuberculous mycobacterial (NTM) infections, was reviewed. Pulmonary function tests (PFTs) were considered to assess lung function. Diagnosis of MAC pulmonary disease is confirmed based on clinical presentation, radiographic findings, and microbiological confirmation. Treatment plan includes a macrolide antibiotic (azithromycin, clarithromycin), ethambutol, and rifampin, with the duration of therapy determined by clinical response and sputum culture conversion. Patient education regarding medication adherence, potential side effects, and follow-up care was provided. ICD-10 code A31.0 (Pulmonary Mycobacterium avium complex infection) and relevant procedural codes for diagnostic tests and treatment administration will be documented. Prognosis and potential complications, including respiratory failure and disseminated MAC infection, were discussed with the patient. Regular monitoring of symptoms, sputum cultures, and pulmonary function is necessary to assess treatment efficacy.